Business Wire

AXA signs agreement to use the Detica NetReveal insurance claims fraud prevention service

Share
DETICA-NETREVEAL/AXA

BAE Systems Detica has announced that AXA has signed up to use its Detica NetReveal insurance claims fraud prevention service as part of an AXA initiative to select a single solution across the group. Detica NetReveal reduces the risk of fraudulent customer claims and improves investigation times for personal and commercial motor and property lines of business.

The selection of this solution followed a number of successful European pilot projects and it will be delivered as a hosted service, enabling AXA to benefit from reduced costs in IT expenditure, for example, and implementation times. As part of a global programme to use a single platform, AXA can benefit from processes, workflows and reporting which are standardised across AXA’s global business units.

By giving investigators the ability to monitor and clearly identify and prioritise suspicious activity as well as quickly access and analyse customer data, AXA entities will be able to improve customer service through faster claims handling times and also minimise the time and resources spent on investigating claims incorrectly flagged as being suspicious.

Pierre Brigadeau, Group Chief Claims Officer, AXA Global P&C, said:

“All insurers need to focus on claims fraud, and Detica NetReveal will provide us with effective means of reducing risk – preventing and discovering more fraudulent claims, improving positive customer service levels and allowing AXA to have more efficient claims organisations.

“In other words, we shall investigate fewer cases, increase our efficiency and preserve honest customers from paying for fraudulent claims activities.

“After a competitive Global RFQ review we selected Detica NetReveal to provide AXA Group with a claims fraud prevention solution that will enable us to focus on obvious fraudulent claims and therefore increase our quality of service while delivering significant savings in indemnity costs.”

Detica NetReveal links related entities within a company’s data to reveal networks of suspicious activity that are otherwise hidden beneath seemingly innocuous claims. Unlike traditional rules-based systems that can only monitor fraud methods already known to occur, the NetReveal solution provides a single view of customers and their known associates, scoring individual and network behaviours across an organisation’s entire portfolio of products and brands. In doing so, it facilitates the speedy resolution of honest claims and effective decision-making at policy inception, whilst uncovering and prioritising the risks associated with suspicious activity.

Andy Cobb, Sales and Marketing Director for Detica NetReveal, said:

“We are delighted to be working with AXA under this Group initiative to adopt our insurance claims fraud prevention solution and harness the cost benefits of our hosted service. We look forward to further consolidating our partnership with AXA Group as this programme is rolled out across the organisation.”

- Ends -

About Detica NetReveal

Detica NetReveal is a leading provider of enterprise risk, fraud and compliance solutions to the global financial services industry and government clients. Its innovative solutions provide a holistic ‘single customer view’ and then combines entity and social network analytics with deep domain expertise. This approach provides an end-to-end enterprise perspective of financial crime and risk for the detection, prevention and monitoring of risk, fraud and non-compliance in real-time and batch. By knowing your customer, what kind of business they transact and who they know, Detica NetReveal can identify unusual and suspicious behaviours faster and earlier than any other current approaches.

With over 100 clients across four continents, including six of the world’s current top 10 financial institutions, Detica NetReveal has established a proven track record of reducing financial losses, protecting users’ reputations and improving operational efficiencies. Detica NetReveal is a business division of BAE Systems Detica. In 2011, BAE Systems acquired Norkom Technologies and merged it with Detica NetReveal.

For further information, please visit www.deticanetreveal.com

About BAE Systems Detica

BAE Systems Detica delivers information intelligence solutions to government and commercial customers. We help them collect, exploit and manage data so they can deliver critical business services more effectively and economically. We also develop solutions to strengthen national security and resilience.

We integrate and deliver world-class solutions to our customers’ most complex operational problems – often applying our own unique intellectual property. Our services include cyber security, managing risk and compliance, data analytics, systems integration and managed services, strategy and business change and the development of innovative software and hardware technologies.

Detica is part of BAE Systems, a global defence and security company with over 100,000 employees worldwide. BAE Systems delivers a full range of products and services for air, land and naval forces, as well as advanced electronics, security, information technology solutions and customer support services.

BAE SYSTEMS, DETICA, NETREVEAL, Detica NetReveal are trade marks of BAE Systems plc.

Contact:

Media:
BAE Systems Detica
Natasha Davies, +44 (0) 20 7812 4274
Mobile: +44 (0) 7787 297 831
Head of PR and Media
Natasha.davies@baesystemsdetica.com
or
Articulate Communications Inc.
Laura Anderson, +1-212-255-0080, ext. 11
landerson@articulatepr.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release

Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i

The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release

Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP

Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release

New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release

- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release

With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye